Quantification of Gadolinium Deposition in the Brain Using Quantitative MRI

Abstract Gadolinium depositions in the brain caused by Gadolinium Based Contrast Agents (GBCAs) represent a topical issue since depositions have been confirmed, but their potential effects remain unknown. The purpose of this study is to show that quantitative MRI provides an alternative to conventional MRI for detection of gadolinium depositions without the need for reference areas, while also avoiding methodological limitations associated with conventional MRI, facilitating future studies on the subject. This retrospective observational cohort study of longitudinally acquired data uses quantitative MRI to quantify gadolinium depositions in six areas of the brain; the dentate nuclei, globus pallidi, thalami, pons, white matter and frontal cortex grey matter of 43 patients who received two to five doses of Magnevist (a linear GBCA) from 2009 to 2015. R1 was measured at baseline and after four years in the six areas of the brain of each patient. The changes in R1 were examined using a Paired-Samples T test. The correlation between doses of Magnevist and R1 was analysed using an Independent-Samples T test. There was a significant increase in R1 (p<0.05), consistent with gadolinium depositions in the dentate nuclei, globus pallidi and grey matter. No significant increase of R1 was found in the thalami, white matter or pons. A correlation between doses of Magnevist and R1 was found in the dentate nuclei and grey matter, but not in the globus pallidus. The results suggest that quantitative MRI is an alternative to conventional MRI for early detection of gadolinium depositions, while additionally providing quantitative measurements for comparison and follow-up.